Prospective studies and next steps

As the demands for clinical use and economic benefits of diagnostics tests have increased significantly in recent years, so has the need for prospective studies. In order to validate the clinical utility of IMMray™ PanCan-d, Immunovia has embarked in large prospective studies.

Currently, the company is involved in three ongoing prospective pancreatic cancer studies focusing on the main risk groups:

  1. PanFAM-1 for Familiar/hereditary pancreatic cancer risk group
  2. PanDIA-1 for New onset diabetes type II – associated pancreatic cancer
  3. PanSYM-1 for risk groups with vague symptom profiles associated to pancreatic cancer

Once the studies are completed, the results will be the basis for applying for IMMray™ PanCan-d reimbursement and inclusion in national guidelines.

Click on image to magnify.


Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports